Results 41 to 50 of about 399,381 (358)

Molecular Biology and Diversification of Human Retroviruses

open access: yesFrontiers in Virology, 2022
Studies of retroviruses have led to many extraordinary discoveries that have advanced our understanding of not only human diseases, but also molecular biology as a whole. The most recognizable human retrovirus, human immunodeficiency virus type 1 (HIV-1),
Morgan E. Meissner   +8 more
doaj   +1 more source

Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection [PDF]

open access: yes, 2003
Liver-related mortality is an increasing problem in human immunodeficiency virus (HIV)/hepatitis B virus (HBV)-coinfected patients receiving highly active antiretroviral therapy (HAART).
Bertoletti, A   +4 more
core   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

HIV/AIDS Associated Lymphoma: Review

open access: yesBlood and Lymphatic Cancer: Targets and Therapy, 2022
Ayenew Berhan,1 Biruk Bayleyegn,2 Zegeye Getaneh2 1Department of Medical Laboratory Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Hematology and Immunohematology, School of Biomedical and Laboratory ...
Berhan A, Bayleyegn B, Getaneh Z
doaj  

Spotlight on HIV-1 Nef: SERINC3 and SERINC5 Identified as Restriction Factors Antagonized by the Pathogenesis Factor

open access: yesViruses, 2015
The Nef protein is an accessory gene product encoded by human immunodeficiency virus types 1 and 2 (HIV-1/-2) and simian immunodeficiency virus (SIV) that boosts virus replication in the infected host and accelerates disease progression. Unlike the HIV-1
Oliver T. Fackler
doaj   +1 more source

Delivery of Islatravir via High Drug‐Load, Long‐acting Microarray Patches for the Prevention or Treatment of Human Immunodeficiency Virus

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Islatravir‐loaded dissolving microarray patches (MAPs) provide a minimally invasive, long‐acting solution for HIV‐1 prevention and treatment. In rats, sustained islatravir delivery lasts up to three months, while in minipigs, efficacious plasma levels are detected for six days.
Qonita Kurnia Anjani   +11 more
wiley   +1 more source

Patterns of HIV/SIV prevention and control by passive antibody immunization

open access: yesFrontiers in Microbiology, 2016
Neutralizing antibody (NAb) responses are promising immune effectors for control of human immunodeficiency virus (HIV) infection. Protective activity and mechanisms of immunodeficiency virus-specific NAbs have been increasingly scrutinized in animals ...
Hiroyuki Yamamoto   +2 more
doaj   +1 more source

Human Immunodeficiency Virus (HIV) Infection

open access: yes, 2018
This chapter discusses the unique problems associated with HIV and pregnancy. It discusses organ complications associated with HIV and vertical transmission.
Cassandra Wasson   +3 more
openaire   +2 more sources

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

open access: yesAdvanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee   +9 more
wiley   +1 more source

Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision

open access: yesAdvanced Healthcare Materials, EarlyView.
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy